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Abstract
Background
Symptomatic intracerebral hemorrhage (sICH) after bridging thrombolysis for acute ische-
mic stroke is a devastating complication. We aimed to assess whether the additional admin-
istration of aspirin during endovascular intervention increases bleeding rates.
Methods
We retrospectively compared bleeding complications and outcome in stroke patients who
received bridging thrombolysis with (tPA+ASA) and without (tPA-ASA) aspirin during endo-
vascular intervention between November 2008 and March 2014. Furthermore, we analyzed
bleeding complications and outcome in antiplatelet naïve patients with those with prior or
acute antiplatelet therapy.
Results
Baseline characteristics, previous medication, and dosage of rtPA did not differ between 50
tPA+ASA (39 aspirin naïve, 11 preloaded) and 181 tPA-ASA patients (p>0.05). tPA+ASA
patients had more often internal carotid artery (ICA) occlusion (p<0.001), large artery dis-
ease (p<0.001) and received more often acute stenting of the ICA (p<0.001). 10/180 (5.6%)
tPA-ASA patients and 3/49 (6.1%) tPA+ASA patients suffered a sICH (p = 1.0). Rates of
asymptomatic intracerebral hemorrhage, systemic bleeding complications and outcome did
not differ between both groups (p>0.1). There were no differences in bleeding complications
and mortality among 112 bridging patients with antiplatelet therapy (62 preloaded, 39 acute
administration, 11 both) and 117 antiplatelet naïve patients. In a logistic regression analysis,
aspirin administration during endovascular procedure was not a predictor of sICH.
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Conclusion
Antiplatelet therapy before or during bridging thrombolysis in patients with acute ischemic
stroke did not increase the risk of bleeding complications and had no impact on outcome.
This finding has to be confirmed in larger studies.
Introduction
Early administration of aspirin after intravenous thrombolysis (IVT) in patients with acute
ischemic stroke increases the risk of symptomatic intracerebral hemorrhage (sICH) and does
not improve outcome [1]. Current stroke guidelines and study protocols do not recommend
the use of antiplatelets or anticoagulants in the first 24 hours after treatment with intravenous
recombinant tissue plasminogen activator (iv rt-PA). [2–5]
IVT followed by endovascular therapy (EVT) is effective in stroke patients with proximal
vessel occlusions [6, 7]. In patients with acute occlusions or relevant stenosis of large extracra-
nial vessels acute stenting is sometimes necessary [8, 9]. Administration of antiplatelets is
required to prevent reocclusion of stents [10, 11]. Furthermore, EVT can cause endothelial
damage resulting in vessel stenosis, dissections and reocclusions [12, 13]. Antiplatelets might
prevent thrombus formation and vessel reocclusion in damaged vessel. However it remains
unclear, whether the potential benefit of antiplatelets during bridging thrombolysis is out-
weighed by bleeding complications.
Based on the current literature we hypothesized an increase in bleeding complications in
bridging patients who receive additional antiplatelet therapy during endovascular interven-
tion. We therefore assessed rates of sICH, asymptomatic intracerebral hemorrhage (aICH),
systemic bleeding complications and outcome in patients with bridging thrombolysis with
(tPA+ASA) and without (tPA-ASA) additional aspirin administration during endovascular
intervention.
Materials and Methods
Patients
This study is based on the Bernese stroke registry, a prospective data collection of patients with
acute ischemic stroke. All patients who received combined IVT and EVT (bridging therapy)
were included in this retrospective analysis. Demographic data, previous medication, vascular
risk factors, laboratory findings, treatment modality, and time from symptom onset to treat-
ment were recorded. Clinical evaluation was performed by a stroke neurologist immediately
after admission in the emergency room using the National Institute of Health Stroke Scale
(NIHSS) score. Stroke etiology was classified according to Trial of ORG 10172 in Acute Stroke
Treatment (TOAST) criteria [14].
Thrombolysis in our institution is performed according to international and institutional
guidelines. The general approach at our centre has been described previously [9, 15, 16].
Immediately after clinical evaluation all patients underwent CT or MR imaging to rule out
intracranial hemorrhage and CT or MR angiography (MRA) to assess vessel occlusion and if
present its location. Intravenous thrombolysis is directly started in the scanner. Patients with
proximal vessel occlusions were considered as candidates for endovascular therapy. Endovas-
cular therapy was performed with the consent of the patient or his family immediately after
CT or MRI if: 1) diagnosis of ischemic stroke was established; 2) baseline NIHSS score was 4
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points or isolated aphasia or hemianopia was present; 3) hemorrhage on cranial CT or MRI
was excluded; 4) vessel occlusion correlated with the neurological deficit; 5) symptom duration
was not longer than 24 hours; and 6) no individual clinical or premorbid conditions or labora-
tory findings advised against thrombolysis [16]. Digital subtraction angiography (DSA) was
performed via a transfemoral approach using a biplane, high-resolution angiography system.
In general, a four vessel cerebral angiography was performed prior to the intervention. Endo-
vascular recanalization procedures consisted of a combination of several approaches depend-
ing on occlusion pattern and operator preference: intra-arterial thrombolysis using urokinase,
mechanical recanalization using direct thrombaspiration through a catheter placed proximal
to the thrombus and stent retrievers retracting the thrombus after stent expansion within in
the thrombus area and placement of extracranial stents with or without pre- or postdilatation.
The interventional neuroradiologists decided together with the stroke neurologist on the use
of urokinase, mechanical intervention and—if necessary—stenting of the extracranial internal
carotid artery (ICA). In general, patients received aspirin intravenously during or immediately
after the endovascular intervention (ASA dosage: mean 341 mg, median 300mg) if stenting
was performed, unless they were already under a treatment with antiplatelets. Dual antiplatelet
therapy was not administrated within the first 24 hours after symptom onset. 24 hours after
treatment, or in any case of clinical deterioration a CT or MRI scan was performed. sICH and
aICH were classified according to the PROACT II study protocol [17]. Furthermore, any sys-
temic bleeding occurrence was documented (excluding local hematoma at the catheter inci-
sion site). Recanalization rates were assessed immediately after angiography using the
thrombolysis in myocardial infarction (TIMI) classification. [18] Furthermore, status of vessel
recanalization was assessed in patients who underwent CT or MR angiography after 24 hours.
In patients with extracranial stenting, information on stent patency was obtained by ultra-
sound and/or CT angiography. Clinical outcome was prospectively assessed 3-months after
the stroke using the modified Rankin scale (mRS). The study was performed according to the
ethical guidelines of the Canton of Bern and with corresponding permission (Kantonale Ethik-
kommission Bern, Ho¨rsaaltrakt Pathologie, Eingang 43A, Bu¨ro H372, Murtenstrasse 31, 3010
Bern).
Statistical Analysis
Statistical analysis was performed using SPSS 21 (SPSS Inc., Chicago, Illinois, USA). We com-
pared baseline characteristics, risk factors, stroke etiology, laboratory findings, blood pressure,
site of vessel occlusion, therapy and outcome between tPA+ASA and tPA-ASA patients. Dif-
ferences between the two groups were assessed using Fisher’s exact test comparison for cate-
gorical variables and Mann Whitney test for comparison of continuous variables. To detect the
influence of any antiplatelet therapy in acute stroke patients who underwent bridging throm-
bolysis, we compared bleeding complications and outcome in antiplatelet naïve patients versus
those with previous or acute antiplatelet therapy. Complete recanalization was defined as
TIMI 3. Outcome was dichotomized into favorable (mRS 0–2) and poor clinical outcome
(mRS 3–6). Logistic regression analysis was used to determine the predictors of sICH and
aICH. We included all variables with a p value <0.2 in the univariate analysis. We analyzed
whether aspirin in combination with aforementioned relevant variables had an impact on
sICH and aICH. A two-sided p value <0.05 was considered statistically significant.
Results
From 1st November 2008 to 31st March 2014 1145 patients received thrombolysis for acute
ischemic stroke. 231 underwent bridging therapy and 50 of these received aspirin intravenously
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in addition to rtPA (39 antiplatelet naïve, 11 preloaded). Baseline characteristics and vascular
risk factors of tPA-ASA and tPA+ASA patients are shown in Table 1.
Therapeutic approaches in both groups are shown in Table 2. Stroke severity (NIHSS
score), risk factors, laboratory findings, blood pressure, time to treatment, preexisting anti-
platelet therapy, and dosage of thrombolytics did not differ between both groups (p>0.05).
tPA+ASA patients were more often men (p = 0.015), were older (p = 0.049), had more often
large artery disease (p<0.001), atrial fibrillation (p = 0.001), ICA occlusions (p<0.001) and
received more often acute stenting of the ICA (p<0.001). Clinical and radiological outcome is
provided in Table 3 and Fig 1. Complete recanalization rate did not differ between tPA+ASA
and tPA-ASA patients (p>0.1). Rates of sICH and aICH, systemic bleeding complications and
outcome did not differ between tPA+ASA and tPA-ASA patients (p>0.1). In a logistic
Table 1. Baseline characteristics and vascular risk factors.
Bridging without ASA (n = 181) Bridging with ASA (n = 50) p
Sex female, n (%) 82 (45.3) 13 (26.0) 0.015
Age, mean (SD) 69 (14) 66 (13) 0.049
NIHSS score, median (range) 15 (2–37) 15 (3–36) 0.493
Vascular risk factors
Diabetes mellitus, n (%) 29/180 (16.1) 12 (24.0) 0.213
Hypertension, n (%) 111/180 (61.7) 34 (68.0) 0.508
Hypercholesterolemia, n (%) 94/179 (52.5) 23/49 (46.9) 0.522
Current smoking, n (%) 36/158 (22.8) 10/44 (22.7) 1.0
Etiology
TOAST
large artery atherosclerosis 15/178 (8.4) 17 (34.0) <0.001
cardioembolism 90/178 (50.6) 8 (16.0) <0.001
small-vessel occlusion 0 0 -
other determined etiology 0 6 (12.0) <0.001
undetermined etiology 73/178 (41.0) 19 (38.0) 0.746
Atrial fibrillation, n (%) 74/153 (48.4) 9/43 (20.9) 0.001
Coronary heart disease, n (%) 31/180 (17.2) 6 (12.0) 0.514
Laboratory findings
INR, mean (SD) 1.06 (0.1) 1.04 (0.8) 0.179
Platelet count, mean (SD) 214 (65) 231 (72) 0.112
Serum glucose, mmol/l, mean (SD) 7.1 (2.1) 7.4 (2.4) 0.250
Blood pressure
Systolic blood pressure on admission, mean (SD) 153 (29) 160 (23) 0.062
Diastolic blood pressure on admission, mean (SD) 82 (18) 88 (20) 0.130
Maximum systolic blood pressure during intervention, mean (SD) 172 (25) 175 (24) 0.436
Maximum diastolic blood pressure during intervention, mean (SD) 85 (18) 91 (18) 0.062
Anterior circulation stroke, n (%) 156 (86.2) 41 (82.0)
ICA 43 (23.8) 30 (60.0) <0.001
M1/2 113 (62.4) 11 (22.0) <0.001
Posterior circulation stroke, n (%) 25 (13.8) 9 (18.0)
BA 23 (12.7) 9 (18.0) 0.357
other 2 (1.1) 0 -
Abbreviations: ASA: Acetyl salicylic acid, SD: standard deviation, NIHSS: National Institutes of Health Stroke Scale, TOAST: Trial of ORG 10172 in Acute
Stroke Treatment, INR: international normalized ratio, ICA: internal carotid artery, M1/2: Segment 1 and 2 of the middle cerebral artery, BA: Basilar artery
doi:10.1371/journal.pone.0170045.t001
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regression model, aspirin administration during endovascular procedure was not a predictor
of sICH and aICH (p>0.05). Diabetes (p<0.038) and NIHSS score (p = 0.036) were indepen-
dent predictors of sICH.
We analyzed bleeding complications and outcome in antiplatelet naïve patients with those
with previous or acute antiplatelet therapy (Table 4). Patients with previous antiplatelet
Table 2. Therapy.
Bridging without ASA (n = 181) Bridging with ASA (n = 50) p
Any preexisting antiplatelets, n (%) 62/179 (34.6) 11 (22.0) 0.122
Aspirin, n (%) 48/62 (77.4) 10/11 (90.9)
Clopidogrel, n (%) 13/62 (21.0) 0
Dual Antiplatelet therapy, n (%) 1/62 (1.6) 1/11 (9.1)
Unclear 2 0
Bridging Thrombolysis
IVT
Minutes from onset to start of IVT, mean (range) 164 (58) 166 (58) 0.654
rtPA dose (mg), mean (SD) 51.5 (14.0) 54.2 (14.1) 0.242
ET
Minutes from onset to start of ET, mean (range) 270 (83) 297 (102) 0.102
Mechanical thrombolysis, n (%) 165 (91.2) 47 (94.0) 0.771
Stenting intervention, n (%) 8 (4.4) 36 (72.0) <0.001
Intracranial stenting, n (%) 3 (1.7) 9 (18.0) <0.001
Extracranial stenting, n (%) 5 (2.8) 32 (64.0) <0.001
Administration of Urokinase, n (%) 51 (28.2) 18 (36.0) 0.298
Combined Urokinase and mechanical thrombolysis, n (%) 35 (68.6) 15 (83.3) 0.358
Combined Urokinase and Stenting, n (%) 3 (5.9) 11 (61.1) <0.001
Urokinase dose (IU), mean (SD) 123000 (238000) 154000 (261000) 0.344
Abbreviations: ASA: Acetyl salicylic acid, IVT: intravenous thrombolysis, ET endovascular thrombectomy, SD: standard deviation
doi:10.1371/journal.pone.0170045.t002
Table 3. Outcome.
Bridging without ASA (n = 181) Bridging with ASA (n = 50) p
Complete vessel recanalization (TIMI 3)
immediately after endovascular intervention 116/179 (64.8) 30 (60.0) 0.618
24 h after endovascular intervention 106/137 (77.4) 25/39 (64.1) 0.101
Complete vessel recanalization (only patients with extracranial stents)
24 h after endovascular stenting 7/8 (87.5)* 31/36 (86.1) 1.0
Bleeding complications
sICH, n (%) 10/180 (5.6) 3/49 (6.1) 1.0
aICH, n (%) 37/180 (20.6) 9/48 (18.8) 0.843
systemic bleeding, n (%) 8 (4.4) 1 (2.0) 0.688
Clinical outcome
favourable outcome (mRS 0–2) after 3 months, n (%) 83/168 (49.4) 17/46 (37.0) 0.182
mortality 41/168 (24.4) 9/46 (19.6) 0.560
Abbreviations: ASA: Acetyl salicylic acid, TIMI: thrombolysis in myocardial infarction, sICH: symptomatic intracerebral hemorrhage, aICH: asymptomatic
intracerebral hemorrhage, mRS: modified Rankin Scale.
*5 out of 8 patients had preexisting antiplatelet therapy (including the patient who did not recanalize completely)
doi:10.1371/journal.pone.0170045.t003
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therapy were older (p = 0.05), more often men (p = 0.031), had a higher NIHSS score (p =
0.008), had more often diabetes (p = 0.014), hypertension (p = 0.004) and coronary heart dis-
ease (p<0.001). Furthermore, they had more often an occlusion of the ICA (p = 0.023) and
were more often treated with extracranial stents (p<0.001). There were no differences in
bleeding complications and mortality among 112 bridging patients with previous or acute
antiplatelet therapy (62 preloaded, 39 acute administration, 11 both) and 117 patients who
were antiplatelet naïve (information on antiplatelet premedication missing in 2 patients).
However, outcome at 3 months was more favorable in antiplatelet naïve patients than in
patients with antiplatelets (p = 0.014).
Discussion
This monocenter study of 231 stroke comparing patients with and without aspirin administra-
tion during bridging thrombolysis has three main findings: 1) There were neither an increase
in sICH or aICH nor in any systemic bleeding complications, neither in univariate analysis
nor in a regression model. 2) Outcome at three months did not differ among both groups. 3)
Even when comparing antiplatelet naïve patients with those receiving antiplatelets prior or
during endovascular intervention there was no difference in bleeding complications and
mortality.
Our findings are in contrast to our hypothesis and the current literature. The ARTIS trial
investigated whether infusion of 300 mg aspirin started within 90 minutes of intravenous
thrombolysis with alteplase resulted in improved functional outcome in 642 patients. [1, 19].
The trial was stopped early because of an increased rate of sICH in the combination group (4%
versus 2%, p = 0.04) with no improvement in outcome. Furthermore, data of the SITS-ISTR
showed an absolute 1.4% increase of sICH in patients with previous use of antiplatelet therapy
with no clear effect on outcome. [20]. In contrast to these studies we could not detect an
increase in rates of sICH, aICH or any bleeding complications, neither in patients receiving
aspirin acutely nor in patients pretreated with antiplatelets. However, compared to the ARTIS
Fig 1. Modified Rankin Scale at 3 months.
doi:10.1371/journal.pone.0170045.g001
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Table 4. Comparison between antiplatelet naïve patients and patients with prior and/or acute antiplatelet therapy†.
Bridging without any Antiplatelets
(n = 117)
Bridging with any Antiplatelets
(n = 112)
p
Baseline
Sex female, n (%) 56 (47.9) 37 (33.0) 0.031
Age, mean (SD) 66 (16) 71 (12) 0.05
NIHSS score, median (range) 14 (8) 17 (7) 0.008
Vascular risk factors
Diabetes mellitus, n (%) 13/116 (11.2) 27 (24.1) 0.014
Hypertension, n (%) 63/116 (54.3) 82 (73.2) 0.004
Hypercholesterolemia, n (%) 55/115 (47.8) 62/111 (55.9) 0.234
Current smoking, n (%) 27/106 (25.5) 19/94 (20.2) 0.404
Etiology
Atrial fibrillation, n (%) 44/96 (45.8) 39/100 (39.0) 0.386
Coronary heart disease, n (%) 7/116 (6.0) 30 (26.8) <0.001
Laboratory findings
INR, mean (SD) 1.05 (0.1) 1.05 (0.1) 0.315
Platelet count, mean (SD) 217 (64) 219 (71) 0.728
Serum glucose, mmol/l, mean (SD) 7.0 (2.1) 7.4 (2.2) 0.121
Blood pressure
Systolic blood pressure on admission, mean (SD) 155 (31) 154 (24) 0.827
Diastolic blood pressure on admission, mean (SD) 83 (18) 83 (20) 0.669
Maximum systolic blood pressure during intervention, mean
(SD)
173 (26) 173 (23) 0.639
Maximum diastolic blood pressure during intervention,
mean (SD)
86 (17) 87 (19) 0.96
Anterior circulation stroke, n (%) 100 (85.5) 96 (85.7) 1.000
ICA 29 (24.8) 44 (39.3) 0.023
M1/2 71 (60.7) 52 (46.4) 0.034
Posterior circulation stroke, n (%)
BA 15 (12.8) 16 (14.3) 0.847
other 2 (1.7) 0 -
Therapy
Any preexisting antiplatelets, n (%) 0 73 (65.2)
Additional ASA during bridging, n (%) 0 50 (44.6)
Bridging Thrombolysis
IVT
Minutes from onset to start of IVT,mean (range) 162 (52) 167 (64) 0.732
rtPA dose, mg iv, mean (SD) 51.9 (13.6) 52.3 (14.7) 0.497
ET
Minutes from onset to start of ET, mean (range) 272 (80) 278 (94) 0.497
Administration of Urokinase ia, n (%) 32 (27.4) 37 (33.0) 0.389
Urokinase dose, IU ia, mean (SD) 127000 (255000) 135000 (232000) 0.463
Mechanical thrombolysis, n (%) 107 (91.5) 103 (92.0) 1.0
Stenting, n (%) 3 (2.6) 41 (36.6) <0.001
Outcome
Complete vessel recanalization (TIMI 3)
immediately after endovascular intervention 77/115 (67.0) 68 (60.7) 0.337
24 h after endovascular intervention 70/94 (74.5) 60/80 (75.0) 1.0
Bleeding complications
(Continued )
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trial aspirin in our study was started more than 90 min after intravenous thrombolysis, which
might partly explain the difference of our results compared to ARTIS and should therefore be
considered in future study protocols. Rates of sICH were in line with the current literature on
bleeding complications after bridging thrombolysis [6].
The rationale behind early administration of aspirin in patients receiving thrombolysis in
previous studies is the prevention of reocclusion after early recanalization. [1]. Early reocclu-
sion after initial recanalization occurs in 14–34% of patients and is associated with clinical
deterioration and poor functional outcome [21–23]. In our study the main reason for aspirin
administration during endovascular procedure was the prevention of acute reocclusion of
extra- and/or intracranial stents. There are no randomized trials assessing the risk and benefit
of antiplatelets for stenting of acute occlusions of extracranial vessels in patients with bridging
thrombolysis. According to a consensus document on carotid stenting, patients should be pre-
treated with dual antiplatelet therapy [24]. The consensus document is mainly based on elec-
tive stenting of extracranial vessels [25–28] and on the evidence of major acute coronary trials,
where early reocclusion of stented vessels is a major challenge [29]. In our study early recanali-
zation rates between tPA+ASA and tPA-ASA patients did not differ and more than 80% of
patients with acute stenting of extracranial vessels had a complete recanalization after 24
hours. However, our data are underpowered to assess the impact of antiplatelet therapy on
recanalization rates after bridging thrombolysis.
Overall, outcome did not differ between tPA+ASA and tPA-ASA patients. Outcome tended
to be more favorable in tPA-ASA patients and was significantly better in antiplatelet naïve
patients despite any differences in bleeding complications. The differences may be explained
by a selection bias. Patients with prior antiplatelet therapy were older, had more comorbidities
and more severe strokes mainly due to more ICA occlusions. The different etiopathogenesis of
both groups reflects the treatment based on current guidelines where acute antiplatelet therapy
is recommended for vessel-occlusions that require stenting in contrary to cardioembolic
strokes. But when starting bridging thrombolysis the underlying stroke-etiology is not always
obvious and the need for additional aspirin therapy in the acute phase just reveals during
endovascular procedure. In a prospective trial the etiological differences should be considered
in subgroup-analyses.
Given the lack of evidence on antiplatelet therapy during bridging thrombolysis, neurolo-
gists and interventional neuroradiologists have to balance the risk and benefit of additional
Table 4. (Continued)
Bridging without any Antiplatelets
(n = 117)
Bridging with any Antiplatelets
(n = 112)
p
sICH, n (%) 7 (6.0) 6/110 (5.5) 1.0
aICH, n (%) 22 (18.8) 23/109 (21.1) 0.740
systemic bleeding, n (%) 3 (2.6) 6 (5.4) 0.325
Clinical outcome
favourable outcome (mRS 0–2) after 3 months, n (%) 60/108 (55.6) 40/104 (38.5) 0.014
mortality 23/108 (21.3) 26/104 (25.0) 0.625
Abbreviations: SD: standard deviation, NIHSS: National Institutes of Health Stroke Scale, INR: international normalized ratio, ICA: internal carotid artery,
M1/2: Segment 1 and 2 of the middle cerebral artery, BA: Basilar artery, ASA: Acetyl salicylic acid, IVT: intravenous thrombolysis, ET endovascular
thrombectomy, TIMI: thrombolysis in myocardial infarction, sICH: symptomatic intracerebral hemorrhage, aICH: asymptomatic intracerebral hemorrhage,
mRS: modified Rankin Scale
†data about antiplatelet premedication missing in 2 patients of whom 1 patient had an aICH
doi:10.1371/journal.pone.0170045.t004
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aspirin administration during the intervention. In our study, bleeding complications in
tPA+ASA patients were not increased. Given the often fatal consequences of proximal vessel
reocclusions the benefit of antiplatelet monotherapy might outweigh the risk of intracerebral
hemorrhage. Therefore, antiplatelet therapy should be considered when stenting of extra- or
intracranial vessels has to be performed. However we cannot conclude from our data, that
antiplatelets should routinely be provided in all patients after bridging thrombolysis.
The most important indication for administration of antiplatelets during endovascular pro-
cedures is the prevention of acute stent reocclusion when permanent stents have to be placed.
Recent development of endovascular stroke treatment directs towards the use of retrievable
stents where there is no indication for antiplatelets in general. But there are other indications
for urgent administration of antiplatelets during endovascular interventions such as acute
myocardial infarction (non STEMI) or severe atherosclerosis with high grade stenosis. There-
fore, we believe that a trial assessing the safety of administration of antiplatelets during bridg-
ing thrombolysis is needed.
Our study has several limitations. First, this is a retrospective monocenter analysis of
patients who underwent bridging thrombolysis with prospective follow-up assessment. Sec-
ond, the number of patients and the number of bleeding complications was relatively low
and the study period was limited from 11/2008 to end of 03/2014, just before the publication
of the results of the major RCTs on EVT. Endovascular stroke therapy has a long tradition in
our center and has been systematically performed in all patients with a proximal vessel occlu-
sion in the anterior circulation, even before the publication of the RCTs. Therefore, the publi-
cation of the trials has not changed our treatment approach and including patients treated
after the publication of the RCTs is unlikely to have influenced the results. Third, the reason
for administration of aspirin during the intervention was mainly based on the decision of the
treating physician and therefore a selection bias is possible. Fourth, the exact timing of Aspi-
rin administration during bridging thrombolysis is not available in our database, making a
time dependent analysis impossible. Fifth pharmacological intraarterial thrombolysis was
performed with Urokinase. In our center, first endovascular stroke procedures were per-
formed with Urokinase in 1992. After the publication of the PROACT II study, which proved
that intraarterial thrombolysis with Pro-Urokinase is beneficial in patients with proximal
middle cerebral artery occlusions we continued to treat patients with Urokinase as first line
therapy for intraarterial thrombolysis. Regular publications of the Bernese Stroke Database
showed promising results with no relevant increase in bleeding complications. Given our
longstanding experience with Urokinase we had no convincing reason so far to change from
Urokinase to intraarterial thrombolysis with rt-PA. However, our study does not give any
information on bleeding complications in patients treated with aspirin in the setting of intra-
arterial administration of rt-PA.
Finally, we were not able to assess infarct volume at baseline and rupture of the blood
brain barrier during follow-up from our dataset; both factors may have an important
impact on hemorrhagic risk. But if hemorrhagic transformation was present on imaging,
this was declared as an aICH and the rates of aICH did not differ significantly between both
groups.
Conclusions
In conclusion, antiplatelets therapy before or during bridging thrombolysis in severely affected
patients with acute ischemic stroke due to large vessel occlusion did not increase the risk of
bleeding complications and had no impact on outcome. However, our findings have to be con-
firmed in randomized controlled trials.
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